Clinical Trials Logo

Citation(s)

A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma

Details for clinical trial NCT00109005